Interestingly, HSV has been genetically modified to create oncolytic viruses that can selectively infect and kill cancer cells while sparing normal cells. One such example is Talimogene laherparepvec (T-VEC), an oncolytic viral therapy approved for the treatment of melanoma. This innovative approach represents a promising avenue for cancer treatment, harnessing the virus's ability to lyse tumor cells and stimulate an anti-tumor immune response.
